Research programme: monoclonal antibody therapeutics - Iontas

Drug Profile

Research programme: monoclonal antibody therapeutics - Iontas

Alternative Names: Anti-notch monoclonal antibodies - Iontas

Latest Information Update: 03 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IONTAS
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Notch receptor antagonists; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Research Cancer; Inflammation

Most Recent Events

  • 03 Aug 2016 Monoclonal antibody therapeutics - Iontas is available for licensing as of 03 Aug 2016. http://www.iontas.co.uk/index.html
  • 03 Aug 2016 Early research in Cancer in United Kingdom (unspecified route)
  • 03 Aug 2016 Early research in Inflammation in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top